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ATRA modulates mechanical 
activation of TGF-β by pancreatic 
stellate cells
Muge Sarper, Ernesto Cortes, Tyler J. Lieberthal & Armando del Río Hernández
The hallmark of pancreatic ductal adenocarcinoma (PDAC) is abundant desmoplasia, which is 
orchestrated by pancreatic stellate cells (PSCs) and accounts for the majority of the stroma surrounding 
the tumour. Healthy PSCs are quiescent, but upon activation during disease progression, they adopt a 
myofibroblast-contractile phenotype and secrete and concomitantly reorganise the stiff extracellular 
matrix (ECM). Transforming growth factor β (TGF-β) is a potent activator of PSCs, and its activation 
requires spatiotemporal organisation of cellular and extracellular cues to liberate it from an inactive 
complex with latent TGF-β binding protein (LTBP). Here we study the mechanical activation of TGF-β 
by PSCs in vitro by investigating LTBP-1 organisation with fibrillar fibronectin and show that all trans-
retinoic acid (ATRA), which induces PSC quiescence, down-regulates the ability of PSCs to mechanically 
organise LTBP-1 and activate TGF-β through a mechanism involving myosin II dependent contractility. 
Therefore, ATRA inhibits the ability of PSCs to mechanically release active TGF-β, which might 
otherwise act in an autocrine manner to sustain PSCs in an active state and a tumour-favouring stiff 
microenvironment.
Pancreatic cancer is a devastating disease with dismal prognosis: it carries an overall 5 year survival rate of 6% and 
it is the fourth most common cancer related death in Western world1. This is due to the aggressive behaviour of 
the disease: it metastasises to other organs and resists conventional chemotherapy, which remain the main chal-
lenges in pancreatic cancer treatment1. PDAC is characterised by an abundant desmoplastic response, defined as 
sustained proliferation and concurrent deposition of altered cancer-supporting ECM by stromal cells, leading to a 
stiff tumour-favouring microenvironment2. This dense desmoplastic PDAC stroma could act as a barrier to chem-
otherapeutic agents by making cancer cells inaccessible which, in part, explains the resistance to treatment3,4. 
Pancreatic cancer-associated PSCs are the major cell type responsible for the characteristic desmoplastic response 
in PDAC by depositing and remodelling tumour-promoting ECM5. Healthy PSCs are quiescent and store retinol 
(vitamin A) in their cytoplasm; however, during pancreatic cancer progression, they lose retinol droplets and 
acquire an activated myofibroblast-like contractile phenotype5.
Transforming growth factor-β (TGF-β ) is a potent cytokine that is integral to many biological events, includ-
ing its well-established role as an activator of PSCs5–11. When PSCs are exposed to exogenous TGF-β , myofibro-
blastic markers such as contractility marker α -smooth muscle actin (α -SMA) are activated, and PSCs increase 
ECM deposition, particularly fibronectin and collagen type-I12–14. In the tumour environment, TGF-β can be 
released from cancer cells, infiltrating immune cells, or atypical acinar cells15. Importantly, PSC activation by 
TGF-β can initiate an autocrine positive feedback loop which perpetuates an activated phenotype16,17.
TGF-β is secreted as the large latency complex, which contains latency associated peptide (LAP) and latent 
TGF-β binding protein (LTBP), and it is stored in the ECM in a latent form by LTBP18,19. TGF-β is activated via 
a cell-based mechanism through cell-generated tension against matrix resistance and integrin activity, which 
leads to detachment from LAP and LTBP9,20,21. Fibronectin binds the LTBP N-terminus, and LTBP organises 
onto fibronectin fibril templates thereby allowing TGF-β to be activated by the cell by releasing it from LTBP22–24. 
It has also been shown that two interrelated mechanical cues, cellular contractility and ECM stiffness, are the 
key elements used by the cell to apply tension on latent TGF-β 23,24. ATRA, a retinoic acid isomer and the active 
metabolite of vitamin A, is known to restore the quiescent phenotype in PSCs as well as reduce concomitant 
ECM synthesis and pancreatic cancer cell invasion25–27. It was recently shown to down-regulate cellular stiffness, 
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contractility, and ECM remodelling by PSCs (unpublished data). ATRA has also been shown to promote cell 
compliance in acute promyelocytic leukemia via cytoskeletal remodelling28. Therefore, we hypothesized that the 
ability of ATRA to promote cell compliance and to reduce ECM remodelling could interfere with the priming and 
activation TGF-β by PSCs. In this study, we characterised the ability of PSCs to organise LTBP-1 in the ECM and 
mechanically activate TGF-β . We show that ATRA down regulates this process through a mechanism involving 
myosin II-dependent contractility and β 1 integrins.
Results
ATRA treated PSCs fail to organise and align LTBP-1 and fibronectin into fibrils. To study how 
PSCs organise the ECM under ATRA treatment, we considered their ability to organise LTBP-1 into fibronectin 
fibrils. The cellular ability to organise LTBP-1 into fibrils has been used before as a standard method to assess 
TGF-β activation24. We first generated an LTBP-1-rich ECM by allowing LTBP-1-transfected HEK-293 cells 
to deposit ECM on glass coverslips for 7 days (Fig. S1a). The HEK-293 cells were then removed with sodium 
deoxycholate (DOC) buffer as described in the materials and methods and in Fig. 1a. We used HEK-293 cells 
because they deposit minimal fibronectin and they were not able to organise LTBP-1 into fibrils (Fig. S1b). After 
removing HEK-293 cells, untreated PSCs (hereafter control) or 10 day ATRA (1 μ M) pre-treated PSCs (hereafter 
ATRA) were seeded on matrices and cultured for a further 2 days, during which time PSCs secrete and incor-
porate fibronectin into the ECM. Endogenous expression of LTBP-1 by PSCs was not detectable during 48 hours 
either on glass coverslips or HEK-293 deposited ECM (Fig. S1c,d). Coverslips were then dual-stained for LTBP-1 
and fibronectin. The ImageJ co-localisation plugin coloc 2 was used determine co-localisation of LTBP-1 and 
fibronectin (Fig. 1a) which quantified the interaction between LTBP-1 and fibronectin. LTBP-1 and fibronectin 
co-immunostaining showed that in ECM that is remodelled by control PSCs, LTBP-1 can be organised onto 
fibronectin-positive fibrils (Fig. 1b). In contrast, LTBP-1 remains in patches when deposited by HEK-293 alone 
(Fig. S1b) as further evidenced by the near zero Pearson correlation coefficient of LTBP-1/fibronectin co-locali-
sation (not shown). Furthermore, LTBP-1 and fibronectin co-localisation was significantly reduced with ATRA 
treatment compared to vehicle treated PSCs (p < 0.001) (Fig. 1b,c). We then analysed the thickness of the co-lo-
calised fibrils as a measure of LTBP-1/fibronectin fibril maturation. The fibril thickness heat-map revealed that 
LTBP-1 and fibronectin co-localised fibril thickness was significantly reduced with ATRA treatment compared to 
the control group (p < 0.001) (Fig. 1c). Thus, ATRA reduced LTBP-1 and fibronectin co-localisation and align-
ment, which is a crucial PSC matrix remodelling behaviour.
Fibronectin splice variants fibronectin-EDA and fibronectin-EDB are expressed by PSCs, and 
LTBP-1 alignment requires fibronectin but is unaffected by fibronectin levels in the ECM. 
Fibronectin is alternatively spliced in wound healing and cancer stroma29; for instance, the fibronectin extra 
domain-A (EDA) isoform is overexpressed in liver tumour vasculature30. To understand whether a similar 
alternative splicing mechanism occurs in PSCs, we examined the expression of fibronectin-EDA, which is the 
major isoform expressed in breast cancer, and fibronectin-EDB, which has been implicated in pancreatic can-
cer microenvironment but of an unknown cellular origin31. Quantitative PCR targeting fibronectin-EDA or 
fibronectin-EDB mRNA showed that both variants are expressed by PSCs and expression levels were significantly 
reduced upon ATRA treatment (p < 0.05, p < 0.01 respectively) (Fig. 2a).
To further dissect whether LTBP-1 fibril formation is dependent on the presence of fibrillar fibronectin, 
fibronectin expression was knocked down by siRNA (50 nM) in control PSCs prior to culturing the cells for 
48 hours on LTBP-1 rich ECM. As a result of fibronectin knockdown, LTBP-1/fibronectin co-localisation and 
fibril thickness were significantly decreased (Fig. 2b,c) (p < 0.001 for both measurements). This demonstrates that 
LTBP-1 fibril formation by PSCs is dependent on fibronectin guidance, and in the absence of fibronectin, LTBP-1 
is not organised in fibrils.
To exclude the possibility that the reduction in fibronectin/LTBP-1 co-localisation and fibril thickness with 
ATRA treatment (Fig. 1) might be simply due to differences in expression of extracellular fibronectin (Fig. 2a), 
control or ATRA treated PSCs were cultured on LTBP-1 rich matrices for 48 hours in the presence of excess 
fibronectin (40 μ g/cm2). Despite excess fibronectin addition to culture media, there was a persistent significant 
decrease in fibronectin/LTBP-1 co-localisation with ATRA treatment (p < 0.001) as observed previously with 
endogenous fibronectin secretion (Fig. 2c). Therefore, PSC-mediated LTBP-1 fibril organisation onto fibrillar 
fibronectin depends on the presence of fibronectin but is insensitive to levels of fibronectin in the ECM. Taken 
together our results indicate that there is a threshold of fibronectin concentration that is needed for LTBP-1/
fibronectin alignment by PSCs, but provided this concentration is present, other cellular mechanisms in PSCs 
control LTBP-1/fibronectin alignment.
LTBP-1 fibril alignment onto fibrillar fibronectin by PSCs is an actomyosin dependent mechanism. 
Because fibronectin/LTBP-1 co-localisation was still significantly down-regulated in ATRA treated PSCs com-
pared to control PSCs even when excess fibronectin is added to culture media, we investigated the role of biome-
chanical reorganisation of ECM by PSCs in vitro. Actomyosin contraction-mediated cellular tension applied to 
ECM is required for LTBP-1 alignment23,24,32. ATRA has been previously shown to reduce cell stiffness (unpub-
lished data) and cell contractility markers α -SMA and vimentin25. Similarly, ATRA reduces expression of cell 
contractility marker vimentin in PSCs seeded on LTBP-1 rich matrices (Fig. S2). Therefore, to understand the 
association between PSC contractility and LTBP-1 organisation in our system, control or ATRA treated PSCs 
were seeded on LTBP-1 rich matrices as previous. PSCs were incubated for 16 hours to allow cell attachment and 
spreading after which, 20 μ M blebbistatin (BBI), which blocks myosin II ATPase activity33, or DMSO vehicle 
was added. Both fibronectin/LTBP-1 co-localisation and the thickness of co-localised fibrils were significantly 
reduced in untreated PSCs when exposed to BBI (p < 0.001, p < 0.05 respectively) (Fig. 3), indicating that LTBP-1 
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incorporation onto fibrillar fibronectin is dependent on actomyosin contraction. No significant differences were 
observed when PSCs were treated with both ATRA and BBI in comparison to ATRA alone (Fig. 3), which indi-
cates that ATRA mainly acts through a reduction of actomyosin contraction. Therefore, inhibition of cell contrac-
tility by ATRA or BBI inhibits biomechanical organisation of LTBP-1 and fibronectin.
PSCs act on LTBP-1 through a β1-integrin mediated mechanism. LTBP-1 carries an arginyl-glycyl- 
aspartic acid (RGD) consensus motif, which could act as a recognition site for RGD binding integrins such as 
the β 1 integrin that is responsible for cell-fibronectin adhesion19,34,35. Moreover, cell adhesion to LTBP-1 can 
be reduced by blocking β 1-integrin in myofibroblasts24. To determine the importance of β 1-integrin activity in 
LTBP-1 fibril organisation by PSCs, prior to culturing on ECM, the control cell group was incubated with 1 μ g/
mL β 1-integrin function blocking antibody (BV7) for 30 minutes. Control PSCs were then seeded onto LTBP-1 
Figure 1. Preparation of LTBP-1 rich ECM and LTBP-1/fibronectin co-localisation by PSCs (a) HEK-293 
were seeded on coverslips and transfected with LTBP-EGFP. After 7 days of culture, HEK-293 cells were 
removed with DOC buffer and replaced by PSCs which secrete fibronectin (FN) into the HEK-293-generated 
ECM. Interaction between LTBP-1 and fibronectin is analysed after 2 days of culture by immunofluorescent 
co-localisation. (b) Colocalisation of LTBP-1 (red) and fibronectin (green) as a result of 10-day treated 
ATRA (1 μ M) PSCs or control PSC incubation. (c) Quantification of colocalisation and fibre thickness. 
Representative for 3 independent experiments;, ** p < 0.01, *** p < 0.001, two-tailed Student’s t-test, error bars 
show means ± SEM.
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Figure 2. Fibronectin alternative splicing in PSCs under ATRA treatment and effect of fibronectin knock-
down and excess fibronectin incubation on fibronectin/LTBP-1 lining (a) Q-PCR targeting fibronectin-EDA or 
fibronectin-EDB mRNA showed a significant decrease in fibronectin-EDA and fibronectin-EDB levels in ATRA 
treatment group in comparison to control PSC cells. (b) Immunostaining images of non-targeting siRNA or 
fibronectin mRNA targeting siRNA treated control PSCs show that in the absence of fibronectin, LTBP-1 fibril 
alignment is significantly down-regulated. (c) Fibronectin/LTBP-1 co-localisation analysis of control PSCs and 
ATRA treatment group cultured in the presence of excess fibronectin revealed a significant decrease in ATRA 
treatment when compared to control. Representative for 3 independent experiments; * p < 0.05, ** p < 0.01,  
*** p < 0.001, two-tailed Student’s t-test, error bars show means ± SEM, A.U. arbitrary units.
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rich matrices and incubated for 48 hours. When β 1-integrin was blocked in control PSCs, the fibronectin/LTBP-1 
alignment was significantly decreased in comparison to untreated group (p < 0.001) (Fig. 4a). Furthermore, 
phalloidin staining showed that the cell area occupied by control PSCs was also significantly reduced after β 
1-integrin inhibition (p < 0.001) (Fig. 4b). These results show that β 1-integrin expression by PSCs is a prerequisite 
for actomyosin-mediated alignment of LTBP-1 and fibronectin.
ATRA inhibits PSC-mediated liberation of bioactive TGF-β from its latent LTBP-1 complex. 
Given that ATRA prevented LTBP-1/fibronectin organisation, we investigated whether this was sufficient to 
inhibit activation of TGF-β from its LTBP-1-bound latent form. To measure the level of TGF-β activated by 
Figure 3. Effect of actomyosin cytoskeleton inhibition on LTBP-1 and fibronectin fibril alignment. 
Fibronectin/LTBP-1 co-localisation and fibril density analysis of immunofluorescent images of BBI or DMSO 
only treatment of PSCs showed a significant difference between control and ATRA group in vehicle control 
condition; however, under BBI treatment control and ATRA groups establish similar fibronectin/LTBP-1 co-
localisation levels and fibre thickness. Representative for 3 independent experiments, *** p < 0.001, one-way 
ANOVA with Tukey’s post-hoc comparison test, error bars show means ± SEM, n.s. not significant.
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PSCs, HEK-293 cells were transfected with whole TGF-β coding vector, left to deposit ECM on glass coverslips, 
then removed as previous. PSCs were then cultured on the ECM for 48 hours in serum-free media. In order to 
assess baseline active TGF-β production by PSCs during 48 hours, control or ATRA treated PSCs were cultured 
on non-transfected HEK-293 derived ECM or glass coverslips in serum free media. Conditioned media was col-
lected after the incubation period to quantify the levels of active TGF-β released from the ECM by PSC activity 
(shown schematically in Fig. 5a). We used a TGF-β reporter cell that carries a luminescent vector fused with 
TGF-β downstream target PAI-promoter (Fig. 5b); this assay allows quantification of bioactive TGF-β to distin-
guish it from latent TGF-β and is more physiologically relevant. Reporter cells were incubated for 3 hours in the 
presence of conditioned media collected from control or ATRA PSCs that were cultured on whole TGF-β matri-
ces. The TGF-β bioassay showed that ATRA treatment significantly reduced active TGF-β levels in the media by 
50% when compared to control (p < 0.05) (Fig. 5b), which is consistent with the decrease in fibronectin/LTBP-1 
fibril alignment with ATRA treatment. Baseline active TGF-β derived from either control or ATRA treated PSCs 
was negligible during 48 hours given that media from PSCs grown on non-transfected HEK-293 derived ECM 
Figure 4. Effect of β 1 integrin inhibition on fibronectin/LTBP-1 co-localisation and cell spreading on LTBP-1 
(a) Immunofluorescent images of control PSCs incubated with β 1 integrin blocking antibody (BV7) showed a 
significant reduction in fibronectin/LTBP-1 co-localisation compared to non-treated group. Co-localised fibre 
thickness was also reduced in β 1 integrin antibody treatment group. (b) Phalloidin immunostaining showed a 
significant reduction in cell area in the control PSCs treated with β 1-integrin function blocking antibody when 
compared to non-treated control PSCs. Representative for 3 independent experiments, 42 cells for DMSO and 
35 cells for BV7, *** p < 0.001, two-tailed Student’s t-test, error bars show ± SEM.
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or on glass coverslips produced minimal active TGF-β signal (Fig. 5b). In addition, there was no significant 
difference in baseline active TGF-β between control or ATRA treated PSCs. Taken together, these findings show 
that ATRA reduced LTBP-1 alignment and fibronectin/LTBP-1 fibril co-localisation by PSCs which indicates a 
reduction in ECM remodelling. Concurrently, we showed that ATRA reduces active free TGF-β which could be 
a result of reduced ECM reorganisation.
Discussion
In this study we showed that PSC contractility controls concomitant ECM remodelling and active TGF-β release 
from the ECM. Furthermore, ATRA treatment significantly suppresses the ECM remodelling capacity of PSCs 
needed to activate TGF-β . We also showed that PSC-mediated LTBP-1 alignment was dependent on fibronectin 
fibril guidance: in the absence of fibronectin, LTBP-1 fibril assembly was diminished. Yet, the effects of ATRA were 
not simply a reflection of fibronectin expression levels by PSCs (as shown by the reduction in fibronectin-EDA 
and fibronectin-EDB expression) because when the system was saturated with excess fibronectin, control PSCs 
were still able to organise significantly higher levels of LTBP-1 fibrils than the ATRA treated PSC group. Instead, 
Figure 5. The effect of ATRA treatment on liberation of TGF-β from its LTBP-1 latent form (a) Whole TGF-
β transfected or non-transfected HEK-293 cells were cultured for 7 days and removed (first arrow). Treated 
or control PSCs were incubated on matrices for 48 hours during which they can release TGF-β from LTBP-1 
into the culture media (second arrow). Active TGF-β containing conditioned culture media was collected. FN, 
fibronectin. (b) Left panel; schematic representation of TGF-β bioassay in which TGF-β reporter cells with 
a luminescence vector were incubated with active TGF-β containing control or ATRA treated PSC culture 
media. After ATRA treatment, TGF-β activation by PSCs was significantly reduced (right panel). There were no 
significant differences in luciferase signal between control and ATRA treated PSCs when cells were seeded on 
non-transfected HEK-293 ECM or on glass coverslips. The active TGF-β signals were negligible in the following 
cases: HEK-293 cells or PSCs seeded on glass and PSCs seeded on matrices previously deposited by non-
transfected HEK-293. Representative of 3 independent experiments; * p < 0.05, two-tailed Student’s t-test, error 
bars show means ± SEM, A.U. Arbitrary units. (c) Summary schematic illustrating the effects PSC deactivation 
on ECM remodeling capacity.
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we found that actomyosin cytoskeletal activity was central for LTBP-1/fibronectin alignment because when acto-
myosin contraction was blocked by BBI, PSCs were unable to organise LTBP-1 into fibronectin fibrils. Treatment 
of ATRA pre-treated PSCs with BBI did not further reduce LTBP-1/fibronectin co-localisation, thereby con-
firming that ATRA acts through an actomyosin-dependent mechanism. Therefore, LTBP-1 fibril alignment is a 
function of cellular contractility and requires fibronectin secretion during TGF-β priming.
The role of α v-integrin on LAP is a well-known mechanism of TGF-β activation9,36; however, the importance 
of the RGD sequence in human LTBP-1 is yet to be elucidated. Here we found that, in PSCs, β 1-integrin activity 
was needed for LTBP-1 fibril alignment and for cell spreading on LTBP-1 rich ECM in concert with fibronectin 
secretion. However, blocking β 1-integrin activity has a widespread effect, and we cannot exclude the possibility 
that blocking β 1-integrin might affect other adhesion-dependent processes and ECM remodelling behaviour.
Given the paramount relevance of the desmoplastic reaction in the stroma of pancreatic tumours, stromal 
modulatory drugs have been shown to be a robust strategy which benefits pancreatic cancer treatment by tar-
geting the tumour promoting ability of PSCs, increasing drug delivery to tumour bed, and reducing cancer 
metastasis4,25,37,38. Stromal reprogramming therefore acts by restoring homeostatic conditions in cancer-related 
microenvironment rather than direct ablation of stromal matrix. ATRA has been shown to restore quiescent 
phenotype in PSCs by inducing transcriptional reprogramming25,39. Here we showed that ATRA treatment weak-
ens the capacity of PSCs to activate TGF-β , and TGF-β biological activity is therefore reduced in vitro (Fig. 5c). 
Our findings contribute to previous findings that show ATRA hampers the active myofibroblast PSC phenotype, 
which is strongly associated with tumour growth and metastasis25,40. Further work is required to determine if 
ATRA abrogation of TGF-β activation is sufficient to inhibit secondary effects in a tumour environment such as 
cancer cell proliferation.
Materials and Methods
Cell culture and reagents. HEK-293 cells were cultured in DMEM with high glucose (Sigma-Aldrich, USA) 
supplemented with 10% FBS (Life Technologies, USA), 2 mM L-glutamine (Sigma-Aldrich, USA), 50 units/ml 
penicillin and 50 μ g/ml streptomycin (Sigma-Aldrich, USA). Primary PSCs were purchased from ScienCell 
Research Laboratories (Carlsbad, USA) and cultured in DMEM/F-12 HAM (Sigma-Aldrich, USA) with 2% FBS 
(Life Technologies, USA), 50 units/ml penicillin and 50 μ g/ml streptomycin (Sigma-Aldrich, USA), and 5 ml 
Fungizone (Life Technologies, USA) at 37 °C and 5% CO2. Both cell types were tested for contamination.
ATRA (Sigma-Aldrich, USA) was prepared in ethanol and PSCs were treated with 1 μ M ATRA to limit cyto-
toxicity under dim light conditions for 10 days. ATRA treatment produced quiescence markers such as retinol 
droplets as described previously25. The control PSC group was established by treatment with ethanol vehicle-only 
for 10 days. Media was replenished every 24 hours. Where indicated, cultures were treated with fibronectin or 
control siRNA (Life Technologies), blebbistatin (Calbiochem, USA) or dimethyl sulfoxide (DMSO), β 1-integrin 
blocking antibody (clone:BV7, ab7168; Abcam, UK) or human plasma fibronectin (FC010) (Millipore, USA).
HEK-293 transfection. HEK-293 cells were seeded on 13 mm uncoated glass coverslips (11 × 104 cells/coverslip), 
incubated overnight, and transfected with 0.75 μ g pSecTag– LTBP-1– EGFP plasmid (courtesy of Dr Boris Hinz, 
University of Toronto, Canada) or whole TGF-β plasmid (courtesy of Daniel Rifkin New York University, USA) 
with JetPrime transfection reagent (Polypus, USA). LTBP-1– EGFP is not loaded with TGF-β whereas whole 
TGF-β plasmids carry TGF-β and LTBP-1. Media was changed after 4 hours. Transfected HEK-293s were incu-
bated on coverslips for 7 days to deposit ECM.
ECM de-cellularisation and remodelling. Sodium deoxycholate (DOC) buffer is a water-soluble, ionic 
detergent commonly used in cell lysis buffers for isolation of cell membrane proteins and lipids. Here we used 
DOC buffer to disrupt the cell membrane and remove HEK-293 cells from 7 day old ECM. It has been shown 
previously that the ECM left behind is DOC resistant24. DOC was prepared with 150 mM NaCl, 50 mM Tris HCl, 
1% NP-40 (v/v) substitute and 0.5% (w/v) sodium DOC (all reagents were purchased from Sigma-Aldrich, USA). 
Ice cold DOC buffer was added to 7 day HEK-293 cultures on coverslips and incubated at 4 °C for 10 minutes 
with gentle agitation. The HEK-293 cell debris was washed twice with PBS. Remaining DOC-resistant ECM was 
incubated with room temperature PBS for 15 minutes. Control or 10-day ATRA treated PSCs (3 × 104 cells) were 
then seeded on top of de-cellularised matrices and left to remodel ECM under pertinent treatment for 48 hours.
Gene knock-down. PSCs were reverse transfected with 50 nM fibronectin specific or non-targeting siRNA 
with JetPrime (Polypus, USA). Prior cell seeded matrices were coated with 200 μ l siRNA solution and incubated 
for 10 minutes, then PSCs were added and cultured.
TGF-β bioassay. Control or ATRA treated PSCs were starved for 48 hours on whole TGF-β matrices 
generated from whole TGF-β transfected HEK-293 or on non-transfected HEK-293 as described previously. 
Conditioned culture media was then collected and stored at − 80 °C until needed. The media was concentrated 
4 times by centrifugation for 2 minutes at 13000 rpm using centrifugal filter units (Amicon Ultra 0.5 ml centrif-
ugal filters, 10 K, UFC501024, USA). MDAMB231 cell line transfected with plasminogen activator inhibitor-1 
(PAI-1) promoter fused with luciferase reporter gene (gifted from Dr Caroline Hill, London Research Institute, 
London) were used to determine the activity of TGF-β in conditioned media. When the reporter cells are incu-
bated with active TGF-β containing culture media, downstream TGF-β proteins SMAD-2 and SMAD-3 are phos-
phorylated, form a complex with SMAD-4, and are transported to the nucleus. This complex targets the PAI-1 
promoter, which in the reporter cells is fused with luciferase. MDAMB231 reporter cells were seeded in 96 well 
plates (4 × 103 cells/well) in DMEM supplemented with 10% FBS. MDAMB231 cells were incubated with concen-
trated PSC culture supernatant or PBS for 3 hours, then washed with PBS and incubated with DMEM + 1% FBS 
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for 16 hours. Luciferase signal was measured with a Luminometer (Fluoroskan Ascent Microplate Fluorometer, 
Thermo Scientific, UK) with Promega dual luciferase kit according to manufacturer’s instructions.
Immunofluorescence. PSCs were fixed with 37 °C 4% paraformaldehyde (PFA) for 10 minutes, blocked 
and permeabilised with 2% BSA and 0.1% Triton X-100 (all Sigma-Aldrich, USA) for 1 hour, incubated with 
primary antibodies (LTBP-1 MAB388, R&D Systems, USA; fibronectin ab2413, Abcam, UK; vimentin MO725 
Dako, Denmark; GFP ab290, Abcam, UK) diluted 1/100 in 2% BSA for 1 hour at room temperature, then washed 
with PBS and incubated with secondary antibodies (Alexa Fluor 488 anti-rabbit, Rhodamine Red™ -X goat anti- 
mouse, Life Technologies, USA) and phalloidin (Alexa Fluor 546, A22283, Life Technologies, USA) 1/400 diluted 
in PBS for 45 min in dark. Coverslips were mounted with ProLong Gold Antifade with DAPI (Life Technologies, 
USA).
Image acquisition and quantitative analysis. Images were taken with a Motic AE31 trinocular inverted 
microscope by Motic Images Plus 2.0 software using 40x objective for fibronectin/LTBP-1 analysis and with 20x 
for phalloidin staining. Co-localisation and fibril density analysis were done with ImageJ (NIH) software by 
choosing 5 similar-sized (702 × 702 pixels) region of interests (ROI) per image in symmetry. Three images were 
analysed per condition per experiment. For 3 experiments, n = 45 per condition. The ROIs were then split into 
red and green channels. The amount of co-localisation of LTBP-1 (red channel) and fibronectin (green channel) 
was analysed with Coloc2 plug-in by obtaining Pearson’s correlation coefficient (R value) which uses deviation 
from mean and is not affected from offset41. In order to analyse the fibril density co-localisation threshold images 
were created, converted into binary and analysed with BoneJ plug-in (NIH) by using thickness option. The inten-
sity of vimentin staining was analysed by quantifying the mean fluorescence intensity (MFI) with ImageJ.
Real-time quantitative polymerase chain reaction (Q-PCR). Total RNA was extracted from 
10-day treated control or ATRA PSCs and reversed transcribed by using a high capacity RNA-to-cDNA kit 
(Applied Biosystems, USA). Q-PCR was performed with SYBR Green Master Mix (Life Technologies, USA) in 
a StepOnePlus™ system (Applied Biosystems, USA) using 100 ng cDNA input. Target gene expression was calcu-
lated upon normalisation against GAPDH housekeeping gene by using 2−ΔΔCT method. Primers sequences were 
as follows; fibronectin-EDA forward; 5′ -TCCAAGCGGAGAGAGT-3′ , reverse; 5′ -GTGGGTGTGACCTGAG-3′ , 
fibronectin-EDB forward; 5′ -CCACCATTATTGGGTACCGC-3′ , reverse; 5′ -CGCATGGTGTCTGGACCAATG-3′ 
and GAPDH forward; 5′ ACAGTTGCCATGTAGACC-3′ , reverse; 5′ -TTTTTGGTTGAGCACAGG-3′ .
Statistical analysis. Control and ATRA treated conditions were compared by two-tailed Student’s t-test 
(GraphPad Prism, San Diego, CA). The p-values less than 0.05 were regarded as significant. For multi group 
comparisons a one-way ANOVA with Tukey’s post-hoc comparison test was used. A single asterisk indicates 
* p < 0.05, a double asterisk indicates * * p < 0.01, and a triple asterisk indicates * * * p < 0.001. Error bars are stand-
ard errors of mean (SEM).
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